FIRE1FAS (Fatty Acid Synthase) Insulin-Responsive Element 1
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
9 January 2014 - Irish healthcare products maker Covidien plc (NYSE:COV) on Thursday said that, together with venture capital specialists Lightstone Ventures and New Enterprise Associates (NEA), it would provide a series A financing of an undisclosed value to local novel therapeutic devices developer FIRE1.
The investment in FIRE1, which was launched by medical device company incubator The Foundry LLC, will allow for developing and commercialising solutions for unmet medical needs, Covidien said.